^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | GB263T (EGFR inhibitor, c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preliminary dose escalation results from a first-in-human, phase I/II study of GB263T, a novel EGFR/cMET/cMET trispecific antibody, in patients with advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).
Published date:
05/25/2023
Excerpt:
Pts with EGFRm NSCLC with prior EGFR TKI and platinum-based chemotherapy were enrolled. GB263T was given at 140-1680 mg….Among five response-evaluable pts, three (60%) achieved stable disease (SD). Tumor shrinkage was observed in all three SD pts, with a maximum reduction of 17% in the target lesion. All three SD pts remained on treatment at data cutoff....Results to date demonstrate a favorable safety profile with early signal of clinical activity.
DOI:
10.1200/JCO.2023.41.16_suppl.e21085
Trial ID:
